US FDA: Biosimilar Labeling Should Rely On Innovator Data
This article was originally published in SRA
Executive Summary
The labeling for biosimilars should rely largely on the relevant safety and effectiveness data used by the corresponding US-licensed innovator medicines, with appropriate product-specific modifications, the US Food and Drug Administration said in a new long-awaited draft guidance document issued on March 311.